There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (SYRS – Research Report), Alpine Immune Sciences (ALPN – Research Report) and TransCode Therapeutics (RNAZ – Research Report) with bullish sentiments.
Syros Pharmaceuticals (SYRS)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Syros Pharmaceuticals, with a price target of $15.00. The company’s shares closed last Tuesday at $2.72.
According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of
Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $12.33, representing a 383.5% upside. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Alpine Immune Sciences (ALPN)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Alpine Immune Sciences, with a price target of $17.00. The company’s shares closed last Tuesday at $11.96.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alpine Immune Sciences with a $22.33 average price target, which is a 91.8% upside from current levels. In a report issued on November 3, Morgan Stanley also maintained a Buy rating on the stock with a $30.00 price target.
TransCode Therapeutics (RNAZ)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TransCode Therapeutics today and set a price target of $3.00. The company’s shares closed last Tuesday at $0.32, close to its 52-week low of $0.28.
According to TipRanks.com, Bodnar has 0 stars on 0-5 stars ranking scale with an average return of
TransCode Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SYRS:
